I’d disagree - it’s not cheap to list on the NASDAQ & oz biotechs taking the plunge have a shocking success rate - shareholders always so pumped on a nasdaq listing and then it drags the price more than helps.
Better of delisting going dark for a year and then listing just in the US or moving the company head office to the US but then whats the point in being listed on the ASX. They don’t like investing in companies with head office 10,000kms away they want to be able to pop in down the road.
ASX is fine
DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-220
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
